149 related articles for article (PubMed ID: 37499745)
21. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.
Yang X; Hu Y; Yang K; Wang D; Lin J; Long J; Xie F; Mao J; Bian J; Guan M; Pan J; Huo L; Hu K; Yang X; Mao Y; Sang X; Zhang J; Wang X; Zhang H; Zhao H
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972389
[TBL] [Abstract][Full Text] [Related]
22. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up.
Boons G; Vandamme T; Mariën L; Lybaert W; Roeyen G; Rondou T; Papadimitriou K; Janssens K; Op de Beeck B; Simoens M; Demey W; Dero I; Van Camp G; Peeters M; Op de Beeck K
Clin Cancer Res; 2022 Jan; 28(2):338-349. PubMed ID: 34759042
[TBL] [Abstract][Full Text] [Related]
24. Leveraging locus-specific epigenetic heterogeneity to improve the performance of blood-based DNA methylation biomarkers.
Miller BF; Pisanic Ii TR; Margolin G; Petrykowska HM; Athamanolap P; Goncearenco A; Osei-Tutu A; Annunziata CM; Wang TH; Elnitski L
Clin Epigenetics; 2020 Oct; 12(1):154. PubMed ID: 33081832
[TBL] [Abstract][Full Text] [Related]
25. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.
Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M
Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629
[TBL] [Abstract][Full Text] [Related]
26. Association of Copy Number Variation Signature and Survival in Patients With Serous Ovarian Cancer.
Graf RP; Eskander R; Brueggeman L; Stupack DG
JAMA Netw Open; 2021 Jun; 4(6):e2114162. PubMed ID: 34181012
[TBL] [Abstract][Full Text] [Related]
27. Use of Enzymatically Converted Cell-Free DNA (cfDNA) Data for Copy Number Variation-Linked Fragmentation Analysis Allows for Early Colorectal Cancer Detection.
Černoša I; Trincado-Alonso F; Canal-Noguer P; Kruusmaa K; Perera-Lluna A
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542469
[TBL] [Abstract][Full Text] [Related]
28. Massively parallel sequencing of cell-free DNA in plasma for detecting gynaecological tumour-associated copy number alteration.
Nakabayashi M; Kawashima A; Yasuhara R; Hayakawa Y; Miyamoto S; Iizuka C; Sekizawa A
Sci Rep; 2018 Jul; 8(1):11205. PubMed ID: 30046040
[TBL] [Abstract][Full Text] [Related]
29. Cell-Free DNA Variables including Gene Mutations in CA15-3 Normal Breast Cancer Reflect Prognosis.
Xu J; Chen W; Sun Z; Peng H; Zhou C; Pan S
Dis Markers; 2022; 2022():5470166. PubMed ID: 35251373
[TBL] [Abstract][Full Text] [Related]
30. Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer.
Wang S; Meng F; Li M; Bao H; Chen X; Zhu M; Liu R; Xu X; Yang S; Wu X; Shao Y; Xu L; Yin R
Am J Respir Crit Care Med; 2023 May; 207(9):1203-1213. PubMed ID: 36346614
[No Abstract] [Full Text] [Related]
31. Detection of ovarian cancer using plasma cell-free DNA methylomes.
Lu H; Liu Y; Wang J; Fu S; Wang L; Huang C; Li J; Xie L; Wang D; Li D; Zhou H; Rao Q
Clin Epigenetics; 2022 Jun; 14(1):74. PubMed ID: 35681212
[TBL] [Abstract][Full Text] [Related]
32. Characterization of fragment sizes, copy number aberrations and 4-mer end motifs in cell-free DNA of hepatocellular carcinoma for enhanced liquid biopsy-based cancer detection.
Jin C; Liu X; Zheng W; Su L; Liu Y; Guo X; Gu X; Li H; Xu B; Wang G; Yu J; Zhang Q; Bao D; Wan S; Xu F; Lai X; Liu J; Xing J
Mol Oncol; 2021 Sep; 15(9):2377-2389. PubMed ID: 34133846
[TBL] [Abstract][Full Text] [Related]
33. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
[TBL] [Abstract][Full Text] [Related]
34. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
Yang X; Zhang K; Zhang C; Peng R; Sun C
BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
[TBL] [Abstract][Full Text] [Related]
35. Applying low coverage whole genome sequencing to detect malignant ovarian mass.
Chen M; Zhong P; Hong M; Tan J; Yu X; Huang H; Ouyang J; Lin X; Chen P
J Transl Med; 2021 Aug; 19(1):369. PubMed ID: 34446054
[TBL] [Abstract][Full Text] [Related]
36. Copy number profiling of circulating free DNA predicts transarterial chemoembolization response in advanced hepatocellular carcinoma.
Dong X; Chen G; Huang X; Li Z; Peng F; Chen H; Zhou Y; He L; Qiu L; Cai Z; Liu J; Liu X
Mol Oncol; 2022 May; 16(10):1986-1999. PubMed ID: 34939323
[TBL] [Abstract][Full Text] [Related]
37. Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening.
Cohen PA; Flowers N; Tong S; Hannan N; Pertile MD; Hui L
BMC Med; 2016 Aug; 14(1):126. PubMed ID: 27558279
[TBL] [Abstract][Full Text] [Related]
38. Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling.
Guo W; Chen X; Liu R; Liang N; Ma Q; Bao H; Xu X; Wu X; Yang S; Shao Y; Tan F; Xue Q; Gao S; He J
EBioMedicine; 2022 Jul; 81():104131. PubMed ID: 35780566
[TBL] [Abstract][Full Text] [Related]
39. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
Tsui DWY; Cheng ML; Shady M; Yang JL; Stephens D; Won H; Srinivasan P; Huberman K; Meng F; Jing X; Patel J; Hasan M; Johnson I; Gedvilaite E; Houck-Loomis B; Socci ND; Selcuklu SD; Seshan VE; Zhang H; Chakravarty D; Zehir A; Benayed R; Arcila M; Ladanyi M; Funt SA; Feldman DR; Li BT; Razavi P; Rosenberg J; Bajorin D; Iyer G; Abida W; Scher HI; Rathkopf D; Viale A; Berger MF; Solit DB
Genome Med; 2021 May; 13(1):96. PubMed ID: 34059130
[TBL] [Abstract][Full Text] [Related]
40. Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients.
Jensen TJ; Goodman AM; Kato S; Ellison CK; Daniels GA; Kim L; Nakashe P; McCarthy E; Mazloom AR; McLennan G; Grosu DS; Ehrich M; Kurzrock R
Mol Cancer Ther; 2019 Feb; 18(2):448-458. PubMed ID: 30523049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]